Back to Journals » Clinical Ophthalmology » Volume 4

The comparison of clinical outcomes of endophthalmitis from fluoroquinolone-resistant and susceptible bacteria

Authors Shirodkar A, Flynn Jr HW, Alliman K, Lalwani GA, Alabiad C, Moshfeghi AA, Miller D

Published 12 April 2010 Volume 2010:4 Pages 211—214


Review by Single anonymous peer review

Peer reviewer comments 3

Anita R Shirodkar, Harry W Flynn Jr, Kyle Alliman, Geeta A Lalwani, Chrisfouad Alabiad, Andrew A Moshfeghi, Darlene Miller

Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA

Purpose: To identify patients who developed acute-onset endophthalmitis after clear corneal cataract surgery, and to compare treatment outcomes between cases caused by fluoroquinolone susceptible organisms versus fluoroquinolone resistant organisms.

Design: Retrospective case series.

Methods: Patients who developed endophthalmitis within six weeks of cataract surgery, and were treated between January 1996 and December 2008 at Bascom Palmer Eye Institute in Miami, Florida, were identified retrospectively. Clinical features, organisms cultured, and visual acuity outcomes were evaluated.

Results: A total of 97 patients met study criteria, and 37 (38%) demonstrated in vitro fluoroquinolone resistance. All fluoroquinolone resistant endophthalmitis in the study was caused by either Staphylococcus epidermidis (n = 32) or Staphylococcus aureus (n = 5). Presenting clinical features were similar between fluoroquinolone resistant and fluoroquinolone susceptible groups. Final visual acuity was ≥20/40 in 49% of fluoroquinolone-resistant cases and 42% of fluoroquinolonesusceptible cases. All fluoroquinolone-resistant isolates were susceptible to vancomycin.

Conclusion: In the current study, approximately one-third of isolates were resistant to fluoroquinolones. There was no significant difference in clinical outcomes in this study, regardless of fluoroquinolone susceptibility.
Keywords: endophthalmitis, fluoroquinolones

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]